$8.78
0.00% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

bluebird bio, Inc. Stock price

$8.78
+1.22 16.20% 1M
-10.19 53.73% 6M
-18.82 68.19% YTD
-19.22 68.64% 1Y
-210.02 95.99% 3Y
-1,135.73 99.23% 5Y
-1,203.83 99.28% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.00 0.00%
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

Key metrics

Market capitalization $85.36m
Enterprise Value $375.37m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.07
P/S ratio (TTM) P/S ratio 1.61
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 144.50%
Revenue (TTM) Revenue $53.12m
EBIT (operating result TTM) EBIT $-318.48m
Free Cash Flow (TTM) Free Cash Flow $-227.02m
Cash position $75.01m
EPS (TTM) EPS $-35.97
P/E forward negative
P/S forward 1.18
EV/Sales forward 5.20
Short interest 26.66%
Show more

Is bluebird bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

bluebird bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a bluebird bio, Inc. forecast:

2x Buy
20%
6x Hold
60%
2x Sell
20%

Analyst Opinions

10 Analysts have issued a bluebird bio, Inc. forecast:

Buy
20%
Hold
60%
Sell
20%

Financial data from bluebird bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
53 53
144% 144%
100%
- Direct Costs 86 86
244% 244%
163%
-33 -33
866% 866%
-63%
- Selling and Administrative Expenses 119 119
17% 17%
225%
- Research and Development Expense 110 110
39% 39%
206%
-262 -262
20% 20%
-494%
- Depreciation and Amortization 56 56
1,183% 1,183%
106%
EBIT (Operating Income) EBIT -318 -318
4% 4%
-600%
Net Profit -293 -293
221% 221%
-551%

In millions USD.

Don't miss a Thing! We will send you all news about bluebird bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

bluebird bio, Inc. Stock News

Neutral
Business Wire
21 days ago
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced new and updated data from LYFGENIA™ (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickle cell disease who have a history of vaso-occlusive events (VOEs). The data will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in an oral presentation ...
Neutral
Business Wire
22 days ago
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with betibeglogene autotemcel (beti-cel, approved commercially as ZYNTEGLO™) in clinical studies. The data was presented today at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. “Updated...
Neutral
Business Wire
24 days ago
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it will proceed with a 1-for-20 reverse stock split (“Reverse Stock Split”) of the Company's common stock following approval by both its Board of Directors and BLUE stockholders at its reconvened annual meeting held on December 4, 2024. As previously announced, the primar...
More bluebird bio, Inc. News

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Obenshain
Employees 375
Founded 1992
Website www.bluebirdbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today